NATERA ($NTRA) posted quarterly earnings results for Q4 2025 on Thursday, February 26th. The company reported earnings of $0.35 per share, beating estimates of -$0.52 by $0.87. The company also reported revenue of $665,500,000, beating estimates of $604,264,860 by $61,235,140.
Stock price change since market close: +1.8%
You can see Quiver Quantitative's $NTRA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
NATERA Insider Trading Activity
NATERA insiders have traded $NTRA stock on the open market 198 times in the past 6 months. Of those trades, 0 have been purchases and 198 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:
- STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 30 sales selling 374,356 shares for an estimated $79,547,849.
- MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 10 sales selling 105,000 shares for an estimated $19,781,053.
- MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 25 sales selling 83,452 shares for an estimated $19,308,528.
- ROELOF BOTHA has made 0 purchases and 11 sales selling 75,000 shares for an estimated $17,708,935.
- SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 30 sales selling 52,491 shares for an estimated $11,643,904.
- JONATHAN SHEENA has made 0 purchases and 58 sales selling 54,913 shares for an estimated $11,363,926.
- HERM ROSENMAN has made 0 purchases and 4 sales selling 48,419 shares for an estimated $11,011,477.
- DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 9 sales selling 26,713 shares for an estimated $6,067,144.
- JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 9 sales selling 25,499 shares for an estimated $5,890,419.
- ROY D. BAYNES has made 0 purchases and 8 sales selling 12,780 shares for an estimated $2,809,688.
- ROWAN E CHAPMAN has made 0 purchases and 3 sales selling 7,116 shares for an estimated $1,520,611.
- GAIL BOXER MARCUS sold 122 shares for an estimated $24,242
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
NATERA Hedge Fund Activity
We have seen 426 institutional investors add shares of NATERA stock to their portfolio, and 356 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- COATUE MANAGEMENT LLC added 2,463,008 shares (+1446.1%) to their portfolio in Q4 2025, for an estimated $564,250,502
- WELLINGTON MANAGEMENT GROUP LLP added 2,420,263 shares (+94.7%) to their portfolio in Q4 2025, for an estimated $554,458,050
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,307,662 shares (-75.7%) from their portfolio in Q4 2025, for an estimated $528,662,287
- JPMORGAN CHASE & CO added 1,225,420 shares (+10.5%) to their portfolio in Q4 2025, for an estimated $280,731,467
- RTW INVESTMENTS, LP removed 1,093,645 shares (-42.2%) from their portfolio in Q4 2025, for an estimated $250,543,133
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,075,426 shares (-9.0%) from their portfolio in Q4 2025, for an estimated $246,369,342
- CITADEL ADVISORS LLC removed 786,720 shares (-87.7%) from their portfolio in Q4 2025, for an estimated $180,229,684
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
NATERA Government Contracts
We have seen $373,895 of award payments to $NTRA over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- TUMOR WHOLE EXOME SEQUENCING (WES) AND PERIPHERAL BLOOD CTDNA TEST TESTING (SINGLE ASSAY) SERVICES AND WES ...: $154,100
- MODIFICATION TO EXTEND THE POP FOR SIX (6) MONTHS: $140,595
- GENETIC TESTING: $79,200
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
NATERA Congressional Stock Trading
Members of Congress have traded $NTRA stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOSH GOTTHEIMER purchased up to $15,000 on 09/22.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
NATERA Analyst Ratings
Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 12/22/2025
- BTIG issued a "Buy" rating on 12/05/2025
- JP Morgan issued a "Overweight" rating on 11/25/2025
- UBS issued a "Buy" rating on 11/18/2025
- Stephens & Co. issued a "Overweight" rating on 11/13/2025
- Morgan Stanley issued a "Overweight" rating on 11/11/2025
- Piper Sandler issued a "Overweight" rating on 11/11/2025
To track analyst ratings and price targets for NATERA, check out Quiver Quantitative's $NTRA forecast page.
NATERA Price Targets
Multiple analysts have issued price targets for $NTRA recently. We have seen 12 analysts offer price targets for $NTRA in the last 6 months, with a median target of $262.5.
Here are some recent targets:
- Patrick Donnelly from Citigroup set a target price of $300.0 on 01/07/2026
- Subbu Nambi from Guggenheim set a target price of $270.0 on 01/05/2026
- Kyle Mikson from Canaccord Genuity set a target price of $285.0 on 12/22/2025
- Luke Sergott from Barclays set a target price of $270.0 on 12/15/2025
- Brandon Couillard from Wells Fargo set a target price of $205.0 on 12/15/2025
- Casey Woodring from JP Morgan set a target price of $260.0 on 12/15/2025
- Mark Massaro from BTIG set a target price of $260.0 on 12/05/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
